NCT01203098View on ClinicalTrials.gov

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
Venous ThromboembolismThromboembolismThrombosisEmbolism and ThrombosisDeep Vein ThrombosisArthroplasty, Replacement, Hip
Interventions
DRUG

DU-176b 15mg

DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.

DRUG

DU-176b 30mg

DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.

DRUG

Enoxaparin sodium 20 mg (=2000IU)

Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.

Trial Locations (3)

Unknown

Osaka

Tokyo

Kaohsiung City

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT01203098 - A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty | Biotech Hunter | Biotech Hunter